The changes requested by the Third Point hedge fund underscore the idea that legacy food brands must radically shake up their portfolios to remain profitable.
NYS Entity Status
NYS Filing Date
AUGUST 13, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2013 - GRIFFIN & BIDWELL LLC
AROUND THE WEB
- Shareholders Demand More Drastic Shifts at Nestlé
By STEPHANIE STROM - Tuesday Jun 27, 2017
- Third Point, a Hedge Fund, Sets Its Activist Sights on Nestlé
By MICHAEL J. de la MERCED - Sunday Jun 25, 2017
The fund, run by Daniel S. Loeb, has called on the Swiss food giant to sell its stake in L’Oréal and move more quickly to adapt to changing consumer tastes.
- Dan Loeb's Third Point Makes Its Largest-Ever Bet With Nestlé Stake
Sunday Jun 25, 2017
Billionaire activist investor Daniel Loeb’s Third Point LLC hedge fund has taken a $3.5 billion stake in Nestlé SA, piling pressure on the world’s largest packaged foods company to find ways to accelerate growth.
- Four Credit Repair Agencies Accused Of Misleading Customers, Charging Illegal Fees
By Ashlee Kieler - Tuesday Jun 27, 2017
Four different “credit repair” operations have been ordered to pay a total of more than $2 million in penalties for allegedly tricking people into thinking their bad credit could be easily fixed.The Consumer Financial Protection Bureau announced today that it filed complaints and proposed judgments against Prime Credit, LLC, IMC Capital, LLC, Commercial Credit Consultants, and Park View Law, …
- Dan Loeb buys a chunk of Nestle, blasts ‘staid’ culture
By Carleton English - Monday Jun 26, 2017
Dan Loeb just placed his biggest bet ever on a chocolate company. The activist investor’s hedge fund Third Point LLC amassed a $3.5 billion stake in Nestle, the world’s largest packaged foods company, representing roughly 1.25 percent of the Swiss-based company’s shares. Loeb is hoping to reinvigorate the brand amid changing food tastes as well...
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]